home / stock / gtbp / gtbp news

GTBP News and Press, GT Biopharma Inc. From 03/22/24

Stock Information
Company Name: GT Biopharma Inc.
Stock Symbol: GTBP
Market: OTC
Website: gtbiopharma.com
Menu
GTBP GTBP Quote GTBP Short GTBP News GTBP Articles GTBP Message Board
Get GTBP Alerts

News, Short Squeeze, Breakout and More Instantly...
GTBP - US Companies Moving the Markets, Morning edition
Fri, Mar 22, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Biolase Inc. (BIOL) rose 52.0% to $0.228 on volume of 76,448,685 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 8.5% to $0.1476 on volume of 32,191,096 shares Nova Lifestyle Inc (NVFY) rose 121.6% to $4.1 on volume of 32,...
GTBP - Canopy Growth, Capricor Therapeutics, GT Biopharma among healthcare movers

2024-03-22 10:00:33 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

GTBP - GT Biopharma announces 1-for-30 reverse stock split

2024-02-01 12:02:00 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma Read the full article on Seeking Alpha For further details see: GT Bio...

GTBP - GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® pla...
GTBP - Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote "FOR" All Proposed Items at the Upcoming Special Meeting of Stockholders

The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (Nasdaq: GTBP) (the “Company”), announced that the two leading independent proxy advisor...

GTBP - GT Biopharma submits IND to FDA for CD33+ leukemia therapy

2023-12-04 10:55:06 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma For further details see: GT Biopharma submits IND to FDA for CD33+ leukemia th...

GTBP - GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced the sub...
GTBP - GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced positiv...

GTBP - GT Biopharma GAAP EPS of -$0.06

2023-11-01 09:35:34 ET More on GT Biopharma Seeking Alpha’s Quant Rating on GT Biopharma Historical earnings data for GT Biopharma Financial information for GT Biopharma For further details see: GT Biopharma GAAP EPS of -$0.06

GTBP - GT Biopharma Reports Third Quarter 2023 Financial Results

IND submission for GTB-3650, 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia, expected in Q4 2023 Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia anticipated in 2024 Cash of approximately $16 million a...
Previous 10 Next 10